Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer

MLA

E. Bennicelli, et al. Phase II Trial of Imatinib, Bevacizumab and Cetuximab plus Modified FOLFOX-6 in Advanced Untreated Colorectal Cancer. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bd5a0eaccebc6b9c39d85953d723834a&authtype=sso&custid=ns315887. Accessed 20 Jan. 2025.

APA

E. Bennicelli, A. Pessino, D. Comandini, F. Caprioni, Giuseppe Fornarini, F. Ansaldi, Alberto Sobrero, Stefania Sciallero, A. Guglielmi, & S. Mammoliti. (n.d.). Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer.

Chicago

E. Bennicelli, A. Pessino, D. Comandini, F. Caprioni, Giuseppe Fornarini, F. Ansaldi, Alberto Sobrero, Stefania Sciallero, A. Guglielmi, and S. Mammoliti. 2025. “Phase II Trial of Imatinib, Bevacizumab and Cetuximab plus Modified FOLFOX-6 in Advanced Untreated Colorectal Cancer.” Accessed January 20. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bd5a0eaccebc6b9c39d85953d723834a&authtype=sso&custid=ns315887.